Hans‐Joachim Helms

Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial

Sara A. Hurvitz, Miguel Martín, W. Fraser Symmans et al. · The Lancet Oncology · 2017 · 529 citations · Full text

Medicine, Oncology, Pharmacology +17

IDH1/2 mutations in WHO grade II astrocytomas associated with localization and seizure as the initial symptom

Florian Stockhammer, Martin Misch, Hans‐Joachim Helms et al. · Seizure · 2012 · 146 citations · Full text

Medicine, Neuroscience, Oncology +13

Durability of esthetic improvement following Icon resin infiltration of multibracket-induced white spot lesions compared with no therapy over 6 months: A single-center, split-mouth, randomized clinical trial

Michael Knösel, Amely Eckstein, Hans‐Joachim Helms · American Journal of Orthodontics and Dentofacial Orthopedics · 2013 · 141 citations

Dentistry, Esthetic Dentistry, Restorative Dentistry +14

RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study

Carmelo Carlo‐Stella, Rita Mazza, Salomon Manier et al. · Blood · 2022 · 90 citations

Medicine, Oncology, Pharmacotherapy +17

Effects of Transcutaneous Spinal Direct Current Stimulation in Idiopathic Restless Legs Patients

Anne-Catherine Heide, Tobias Winkler, Hans‐Joachim Helms et al. · Brain stimulation · 2014 · 85 citations · Full text

Medicine, Neurology, Rehabilitation Medicine +9